Tightly regulated at the level of transcription, expression of MHC class II molecules varies significantly among gastrointestinal cancers. High levels of MHC class II expression are often associated with a better prognosis, which is indicative of the involvement of CD4 þ lymphocytes in tumor suppression, but the molecular mechanism by which MHC class II expression is regulated remains unclear. In the present study, we investigated the expression of one inducible MHC class II molecule, HLA-DR, and its coactivators in a panel of colorectal and gastric cancer cell lines. Interferon-c induced expression of HLA-DR in 14 of 20 cell lines tested; the remaining six cell lines did not express HLA-DR. Analysis of the expression of transcription factors and coactivators associated with HLA-DR revealed that the loss of CIITA expression was closely associated with the absence of HLA-DR induction. Moreover, DNA methylation of the 5 0 CpG island of CIITA-PIV was detected in all cancer cells that lacked CIITA. The methylation and resultant silencing of CIITA-PIV depended on the activities of two DNA methyltransferases, DNMT1 and DNMT3B, and their genetic inactivation restored CIITA-PIV expression. It thus appears that CIITA methylation is a key mechanism that enables some gastrointestinal cancer cells to escape immune surveillance.
Introduction
Gastrointestinal cancer is one of the most common of human neoplasias (Neugut et al., 1996; Landis et al., 1999) . It is noteworthy, in that regard, that because the strength of immune responses against colorectal and gastric cancers varies among patients, in many cases tumor cells to able to escape immune surveillance (Kaklamanis and Hill, 1992) . In part, this reflects the cancer cells' loss of MHC molecules (Garrido and Algarra, 2001) . Much attention has been paid to the role of CD8 þ lymphocytes in antitumor immunity, as these cells are able to lyse tumor cells directly upon recognition of peptide-MHC class I complexes expressed by the tumor. However, recent evidence suggests that CD4 þ lymphocytes also play an important role in tumor rejection (Toes et al., 1999; Ossendorp et al., 2000) . In fact, expression of MHC class II molecules is now known to be associated with a better prognosis in colorectal cancer (Lovig et al., 2002) . Expression of MHC class II is induced by interferon (IFN)-g and is tightly regulated at the level of transcription by several RFX family genes (RFX-5, RFX-AP, RFX-B and RFX-ANK) and the transactivator CIITA (Ting and Trowsdale, 2002) . Little is known about the molecular mechanisms underlying the differential expression of MHC class II molecules in gastrointestinal cancers, however.
CIITA is a non-DNA binding coactivator of MHC class II molecules. Four isoforms of CIITA are transcribed from four different first exons (CIITA-PI to CIITA-PIV): promoters (P) I and III are involved in constitutive expression of CIITA in dendritic cells and B lymphocytes (Muhlethaler-Mottet et al., 1997) ; PII has been described only in human cells, though its biological function remains unknown; and promoter PIV is involved in IFN-g inducible gene expression and phosphorylation of STAT1 (Muhlethaler-Mottet et al., 1997) .
Epigenetic mechanisms contribute to the regulation of gene expression by modifying the structure of the chromatin (Jones and Baylin, 2002) . A variety of genes involved in cell cycle regulation, apoptosis and cell signaling are reportedly inactivated by DNA methylation in human cancers (Baylin et al., 2001; Santini et al., 2001) , but little is known about the epigenetic regulation of genes involved in immune responses. In the present study, therefore, we used a panel of colorectal and gastric cancer cell lines to examine the expression of one inducible MHC class II molecule, HLA-DR, and its association with the expression of the transactivators RFX-5, RFX-AP and CIITA. We found that the absence of HLA-DR induction by IFN-g was closely associated with the silencing of CIITA-PIV expression caused by DNA methylation in the region around the transcription start site, and with deacetylation of histone and methylation of histone H3 lysine 9. We believe these findings provide a clue to the mechanism by which colorectal and gastric cancer cells escape immune surveillance.
Results

IFN-g-induced HLA-DR expression
We examined the expression of HLA-DR in colorectal and gastric cancer cell lines using RT-PCR with cDNA prepared from 20 cancer cell lines that had been incubated for 48 h with 100 U/ml IFN-g ( Figure 1a and Table 1 ). Whereas none of the cell lines except KatoIII expressed HLA-DR before treatment with IFN-g, afterward HLA-DR was readily detectable in 14 cell lines (SW48, DLD-1, LoVo, HT29, Colo320, HSC39, HSC40, HSC44, HSC45, MKN7, MKN45, KatoIII, NUGC3, NUGC4); the remaining six (Caco2, RKO, HCT116, MKN28, MKN74 and AZ521) continued to show no expression at all. That cell surface expression of HLA-DR protein was well correlated with expression of HLA-DR mRNA (Figure 1b) indicates that the expression of this molecule is controlled at the level of its transcription. Both differentiated and undifferentiated adenocarcinoma cell lines tended to show an absence of HLA-DR expression; among the former only 3/7 (43%) expressed HLA-DR, while among the latter 2/5 (40%) did so. Although this was a somewhat higher frequency than was seen with the signet-ring cell type (0/6, 0%), no statistically significant difference was found in either case (Fisher's exact test, two-sided; P ¼ 0.25 and 0.46).
Analysis of the STAT1 signaling pathway in colorectal and gastric cancer cells STAT1 signaling is reportedly altered in a subset of gastric cancer cells (Abril et al., 1998) . We therefore explored the possibility that impairment of the signaling pathway leading to STAT1 activation is associated with the loss of HLA-DR from gastrointestinal cancer cells by evaluating STAT1 phosphorylation in several cell lines. After treatment with IFN-g, the cells were labeled with antiphospho-STAT1 antibody (Figure 2a, b) . The majority of cells showed strong nuclear accumulation of the antibody, regardless of whether or not HLA-DR was expressed. We then examined expression of STAT1 in both HLA-DR-positive and HLA-DR-negative cell lines ( Figure 2c ) and found STAT1 protein to be expressed in all cell lines tested. Finally, we examined the expression of IRF-1, a downstream target gene of STAT1 in both HLA-DR-positive and HLA-DRnegative cell lines ( Figure 2d ) and detected its expression in all cell lines examined. Apparently, impaired STAT1 activation was not responsible for the loss of HLA-DR induction by IFN-g.
Expression of transcription factors and coactivators of MHC class II
To determine the extent to which loss of HLA-DR expression was related to a change in the gene's transcription, we next examined the expression of RFX5, RFXAP and CIITA, three transcription factors Integrity of the mRNA was confirmed by amplifying GAPDH.
known to be involved in regulating IFN-g-induced HLA-DR expression (Figure 3a, b) . Expression of both RFX and RFXAP was readily detectable in all cell lines tested. Moreover, when the expression levels of three CIITA isoforms were separately examined using primers that specifically amplified each isoform (Figure 3a) , we found that expression of CIITA-PI and PIII was always very weak or absent (data not shown), but that expression of CIITA-PIV was well correlated with HLA-DR expression. To confirm the extent to which CIITA-PIV expression affects HLA-DR expression, we introduced CIITA-PIV into RKO cells and found that the exogenous molecule restored expression of HLA-DR, even in the absence of IFN-g (Figure 3c and d). CIITA-PIV thus appears to be a critical regulator of HLA-DR expression.
CpG island methylation of CIITA-PIV
Using Blast (http://www.ncbi.nlm.nih.gov/BLAST/) and CpG island Searcher (http://www.uscnorris.com/ cpgislands/), we found that the 5 0 region of CIITA-PIV contains a CpG island that spans 500 bp (CpG:GpC ¼ 0.65, GC% ¼ 55%) (Figure 4a ). Then using four sets of primers, we carried out a combined bisulfite restriction analysis (COBRA) of the entire CpG island of CIITA-PIV. Although methylation of the edges of the CpG island (regions 1 and 4) was detected in virtually all cell lines tested, methylation of the region around exon 1 of CIITA-PIV (regions 2 and 3) was detected only in cell lines where IFN-g-induced expression of CIITA-PIV mRNA was absent (Figure 4b ). Furthermore, bisulfite-sequencing confirmed that in cell lines methylated in regions 2 and 3, virtually all available CpG sites were methylated ( Figure 5 ). Methylation of CIITA-PIV was also detected in five of 32 (16%) primary gastric cancers, indicating that this epigenetic change is not a cell line-specific phenomenon (Figure 4c ).
When we correlated CIITA-PIV expression with the methylation pattern determined by COBRA, we found that whereas methylation of regions 1 and 4 had no effect on gene expression, there was a strong correlation between methylation of regions 2 and 3 and expression ( Figure 6 ). Indeed, IFN-g induced expression of CIITA in all cell lines that lacked methylation in regions 2 and 3, but in none of the cell lines methylated in those regions.
Role of histone modification in the silencing of CIITA gene expression
To determine the histone acetylation status among the methylated CIITA genes, we carried out chromatin immunoprecipitation (ChIP) assays in eight cancer cell lines, with or without CIITA methylation, using primers that amplify selected regions of the CIITA-PIV CpG island (Figure 7a-c) . Little acetylation of histone H3 was noted among the cell lines treated with mock. After treatment with IFN-g, however, histone acetylation was induced in HT29 cells, but remarkably suppressed in other six cell lines that showed CIITA-PIV methylation. When ChIP assays were carried out using anti-acetyl histone H3 antiserum and anti-dimethyl histone H3 lysine 9 (H3K9) antibody, acetylation of histone H3 was readily detectable after treatment with IFN-g in HT29 and MKN45 cells, which also express CIITA-PIV (Figure 7c, d ). By contrast, acetylation of histone H3 remained low in MKN28 cells, which do not express CIITA-PIV. Because methylation of histone H3K9 was recently shown to be correlated with gene silencing (Fahrner et al., 2002; Nguyen et al., 2002; Kondo et al., 2003) , we also carried out ChIP analysis using antidimethyl-histone H3K9 antibody and found that the level of histone methylation is higher in MKN28 cells than in MKN45 or HT29 cells. After treatment with IFN-g, histone methylation remained high in MKN28 cells, but declined in MKN45 and HT29 cells. In sum, the overall acetylation of histone H3 was directly related to CIITA-PIV gene expression, while methylation of histone H3K9 was inversely related to the expression.
Role of DNA methyltransferase in silencing CIITA-PIV gene expression
The role of DNA methyltransferases in silencing CIITA-PIV gene expression was evaluated by using COBRA to examine the methylation status of the 5 0 region of CIITA-PIV in DNMT1À/À, DNMT3BÀ/À and DNMT1À/ÀDNMT3bÀ/À (DKO) cells, which were established from the HCT116 colorectal cancer cell line (Rhee et al., 2002) . Only slight demethylation was observed in DNMT1À/À cells, and no demethylation at all was seen in DNMT3bÀ/À cells ( Figure 8a ). On the other hand, significant demethylation was observed in DKO cells, indicating that disruption of DNMT1 and DNMT3B leads to demethylation of CIITA-PIV ( Figure 8a ). Bisulfite-sequencing confirmed that significant demethylation of the entire CpG island occurred only in DKO cells (Figure 8b ). Moreover, this demethylation led to restoration of expression of two genes, HPP1/TPEF and COL1A2, which had previously been shown to be silenced in colorectal cancer (Figure 8c ), as had p16INK4A, TIMP3 and CHFR (Liang et al., 2000; Rhee et al., 2002; Sengupta et al., 2003; Toyota et al., 2003) . Still, CIITA-PIV gene expression was induced only after IFN-g was added (Figure 8c ), which indicates that, even in the absence of CpG methylation, transcription factor stimulation is necessary for CIITA-PIV gene expression.
The fact that HLA-DR was induced when IFN-g was added to DKO cells is indicative of the key role played by epigenetic control of CIITA-PIV in the expression of HLA-DR. That role was confirmed by our finding that expression of CIITA-PIV and HLA-DR in two colorectal cancer cell lines was restored only when cells were treated with both 5-aza-dC, a methyltransferase inhibitor, and IFN-g (Figure 8d ).
Finally, we examined the extent to which methylation of CIITA-PIV is correlated with absence of HLA-DR expression in 10 primary gastric cancers. Immunohistochemical staining showed that of the three gastric cancers with CIITA methylation none expressed (Figure 9 ). By contrast, of the seven gastric cancers without CIITA methylation, three strongly expressed HLA-DR, two weakly expressed it and two showed no expression. Thus, methylation of CIITA appears also to play a role in the absence of HLA-DR in primary tumors.
Discussion
For unknown reasons, gastrointestinal cancer cells often do not express MHC class II molecules (e.g., HLA-DR), which are associated with T-cell-mediated antitumor immune responses (McDougall et al., 1990; Lovig et al., 2002) . In that regard, the prognoses of colorectal cancers strongly correlate with the infiltration of CD4 þ lymphocytes, which recognize tumor antigen presented with MHC class II molecules (Andersen et al., 1993; Lovig et al., 2002) , so that colorectal cancers that lack HLA-DR have worse prognoses than those that do (Lovig et al., 2002) . For these reasons, understanding the molecular mechanisms regulating expression of MHC class II molecules may represent an important step toward developing efficient immunotherapies with which to treat gastrointestinal cancers. Indeed, several reports suggest that forced expression of MHC in cancer cells leads to loss of tumorigenicity (Armstrong et al., 1997 (Armstrong et al., , 1998 . In the present study, we found that aberrant methylation of CIITA-PIV silences IFN-ginduced HLA-DR expression in colorectal and gastric cancer cells. Conversely, Meazza et al. reported that introduction of CIITA leads to upregulation HLA-DR expression and T-cell activation in mammary adenocarcinomas, which in turn leads to rejection of the tumor cells . Obviously, further study will be necessary to clarify whether in vivo epigenetic restoration of CIITA induces activation of immune surveillance, but the fact that the loss of HLA-DR is caused by epigenetic inactivation of CIITA suggests restoration of CIITA expression may be a useful therapeutic target. Furthermore, the fact that methylation of CIITA occurs less frequently than the loss of HLA-DR indicates that other mechanisms (e.g., altered histone modification) also contribute to the silencing of MHC class II molecules.
Expression of HLA-DR is controlled by mediators downstream of IFN-g, including JAK/STAT and transactivators such as CIITA, RFX5, RFXAP and NF-Y (Ting and Trowsdale, 2002) . The absence of MHC class II could thus be the result of a variety of defects in the transcription machinery. For instance, genetic defects in CIITA and RFX cause severe immunodeficiency called bare lymphocyte syndrome (BLS); impairment of STAT1 has been observed in a subset of gastric cancers (Abril et al., 1998) ; and IRF-1 (Yazawa et al., 2002) . In the present study, however, we confirmed that the inability of IFN-g to induce HLA-DR expression in some cancers was not the result of defects in either STAT1 activation or IRF-1 expression. CpG dinucleotides are sparsely distributed in the 5 0 region of HLA-DR, and so do not satisfy the criteria for a CpG island. Consequently, methylation of HLA-DR may not be the cause of the gene silencing. In fact, we found that introduction of exogenous CIITA into cells that did not express the molecule endogenously induced expression of HLA-DR, even in the absence of IFN-g (Figure 3b , c). This confirms that the HLA-DR promoter is functional, and that the loss of HLA-DR expression is not due to a general defect in the IFN-g signaling pathway. It also shows that suppression of CIITA is exclusively responsible for the loss of HLA-DR expression in colorectal and gastric cancer cells. (Waldburger et al., 2001 ). In the current study, we found that colorectal and gastric cancer cells respond to IFN-g, but that CIITA-PIV is expressed only if the promoter region is not methylated.
The Figure 6 Correlation between methylation of the CIITA-PIV CpG island and induction by IFN-g. The percentages of methylated alleles were determined by bisulfite-PCR as in Figure 4 ; the average of the methylated alleles at each site is shown in black within the circles. The 14 cell lines belonging to Group 1 (SW48, DLD-1, LoVo, GT29, Colo320, HSC39, HSC40, HSC44, HSC45, MKN7, MKN45, KatoIII, NUGC3, NUGC4) expressed CIITA-PIV after treatment with IFN-g; the six cell lines belonging to Group 2 (Caco2, RKO, HCT116, MKN28, MKN74, AZ521) did not express the gene hand, the silencing of CIITA-PIV in head and neck cancers, neuroblastoma and small cell lung cancer is apparently caused by other mechanisms (Yazawa et CIITA-PIV has a small CpG island that spans about 500 bp (CpG : GpC ¼ 0.65, GC% ¼ 55%). Until now, analysis of CIITA-PIV methylation has been limited to the region around exon 1; however, we used semiquantitative methylation analysis to examine the entire CIITA-PIV CpG island. We found that the edge of the island was methylated regardless of gene expression, but that the region around the transcription start site of CIITA-PIV was methylated exclusively in cell lines that do not express CIITA. The reason DNA methylation at the edge of CpG island does not affect gene expression is unknown, though the fact that cell lines showing methylation around the transcription start site were also more densely methylated at the edge of CpG island suggests the edge may serve as a trigger for methylation.
How DNA methylation silences cytokine-induced gene expression is also not fully understood. Recently, however, deacetylation of histone was shown to be involved in gene silencing (Jones and Baylin, 2002) . To investigate the role of histone modification in the silencing of CIITA-PIV gene expression, we carried out ChIP assays using primers that covered the entire 5 0 region of CIITA-PIV. The results showed that the silencing of CIITA-PIV expression in colorectal and gastric cancer cells is closely associated with deacetylation of histone in the 5 0 region of the gene. Treatment with IFN-g induced significant acetylation of histone in unmethylated cell lines but not in methylated ones, which suggests that the structure of the chromatin in the promoter region of methylated genes preferentially recruits histone deacetylase over histone acetyltransferase. In addition, recent reports suggest that histone methylation also contributes to gene silencing (Nguyen et al., 2002; Fahrner et al., 2002; Kondo et al., 2003) , and we were able to show for the first time that histone methylation plays a role in silencing CIITA-PIV gene expression. That a small amount of methylation of histone H3K9 was observed before treatment with IFN-g, even in unmethylated cell lines, suggests histone methylation is regulated by both DNA methylationdependent and -independent mechanisms. Overall, there appears to be an inverse relationship between histone acetylation and histone methylation.
DNA methylation is regulated by three DNA methyltransferases, DNMT1, DNMT3A and DNMT3B, and DNA methylation is reduced by greater than 95% globally in colorectal cancer cells that lack both DNMT1 and DNMT3B (DKO cells) (Rhee et al., 2002) . These changes result in the loss of insulin-like growth factor II (IGF2) imprinting and restoration of p16INK4A, TIMP3 and other cancer-related genes, including CHFR, HPP1/TPEF and COL1A (Liang et al., 2000; Rhee et al., 2002; Sengupta et al., 2003; Toyota et al., 2003) . Thus, DNMT1 and DNMT3b play critical roles in the gene silencing associated with gastrointestinal cancer. Consistent with those results, significant demethylation of CIITA-PIV was observed in DKO cells but not in DNMT1À/À or DNMT3BÀ/À cells, which indicates that both DNMT1 and DNMT3B catalyse methylation of the 5 0 CpG island of CIITA-PIV. Although DKO cells showed demethylation, expression of CIITA-PIV was observed only when IFN-g was added, which means that in addition to an unmethylated promoter, expression of CIITA-PIV also requires stimulation by transcription factors. In summary, we have shown that epigenetic silencing of CIITA-PIV is responsible for the loss of IFN-ginduced HLA-DR expression in colorectal and gastric cancer cells. It is plausible that reactivation of CIITA may lead to immune system activation, making epigenetic activation of CIITA-PIV a potential target of immune therapy. Further study should clarify whether restoration of CIITA-PIV expression in cancer cells will contribute to the upregulation of antitumor immune responses.
Materials and methods
Cell lines and specimens
In all, 15 gastric cancer and eight colon cancer cell lines were used for methylation analysis. Of these, eight gastric cancer cell lines (MKN7, MKN28, MKN45, MKN74, KatoIII, AZ521, NUGC3 and NUGC4) and eight colon cancer cell lines (Caco2, RKO, SW48, HCT116, DLD1, LoVo, HT29 and Colo320) were obtained from either the American Type Culture Collection (Manassas, VA, USA) or the Japanese Collection of Research Bioresources (Tokyo, Japan). Seven gastric cancer cell lines (HSC39, HSC40, HSC41, HSC42, HSC43, HSC44 and HSC45) were kindly provided by Dr Yanagihara of the National Cancer Center Research Institute. All cell lines were cultured in appropriate media. In addition, 32 primary gastric cancer specimens and corresponding normal tissues were acquired from the Department of Surgery, Sapporo Keiyukai Hospital after obtaining informed consent from each patient.
For experimentation, cells were treated for 48 h with 100 U/ ml of IFN-g kindly provided by Shionogi Pharmaceutical (Osaka, Japan) and then harvested. The DNA was then extracted using the phenol/chloroform extraction method, while total RNA was extracted using ISOGEN (Nippon Gene, Japan) according to the manufacturer's instructions. DNMT1À/À, DNMT3bÀ/À and DNMT1À/ÀDNMT3bÀ/ À (DKO) cells were kindly provided by Dr Kornel E Schuebel of the Johns Hopkins Medical Institutions and were described previously (Rhee et al., 2000 (Rhee et al., , 2002 .
Combined bisulfite restriction analysis (COBRA)
COBRA, a semiquantitative analysis of DNA methylation, was carried out as described previously (Xiong and Laird, 1997) . Initially, genomic DNA was treated with sodium bisulfite (SIGMA) as described previously (Clark et al., 1994) . Briefly, 2 mg of DNA were denatured for 10 min at 371C in 2 M NaOH, after which 30 ml of 10 mM hydroquinone (Sigma Chemical Co) and 520 ml of 3 M sodium bisulfite (pH 5.0) were added, and the resultant mixture was incubated for 16 h at 501C. The modified DNA was then purified using a Wizard DNA Purification System (Promega, Madison, WI, USA), after which it was again treated with NaOH and precipitated. Finally, the DNA precipitate was resuspended in 20 ml of TE buffer and stored at À201C until use.
For COBRA, PCR was performed in a volume of 50 ml containing 1 Â PCR buffer (67 mM Tris-HCl, pH 8.8, 16.6 mM (NH 4 ) 2 SO 4 , 6.7 mM MgCl 2 , and 10 mM beta-mercaptoethanol) containing 0.25 mM dNTP mixture, 0.5 mM each primer and 1.0 U of Hot Start Taq polymerase (TaKaRa). Touchdown PCR was then carried out using the primer sequences and restriction enzymes listed in Table 2 . Primers were designed based on the nucleotide sequences obtained from Genbank (AC023047). Samples (20 ml) of PCR product were digested with restriction enzymes that cleave CpG sites retained because of methylation. After ethanol precipitation, the DNA was subjected to 3% agarose gel electrophoresis and stained with ethidium bromide.
Sequence analysis
To sequence bisulfite-PCR products, fragments amplified using primer CIITAGM1-F and SeqR-R were cloned into pCR4 vector using a TOPO-cloning Kit (Invitrogen), after which plasmid DNA was purified using an automated DNA purification system (PI100, Kurabo, Tokyo, Japan). To perform direct sequencing, amplified RT-PCR products were electrophoresed in 1% Seaplaque gels, excised and purified using a PCR Purification System (Promega). The cycle sequencing reaction was carried out using a BigDye terminator kit, after which the DNA was sequenced using an ABI 3100 automated sequencer (Applied Biosystems).
RT-PCR
Total RNA was prepared from samples of gastric and colorectal cancer cell lines, after which 5-mg samples were reverse-transcribed using Superscript II (Invitrogen) to prepare first-strand cDNA. Primer sequences and PCR parameters are shown in Table 2 . To separately amplify the three CIITA isoforms, primers were designed based on the sequences of CIITA-PI, -PIII and -PIV (AF000002, AF000003, AF000004), as shown in Figure 3a . Controls consisted of RNA treated identically but without the addition of reverse transcriptase and are labeled as RT-. The integrity of the cDNA was confirmed by amplifying GAPDH as described previously (Suzuki et al., 2000) . Samples (10 ml) of amplified product were subjected to 2.5% agarose gel electrophoresis and stained with ethidium bromide.
Western blot analysis
Cells were lysed in ice-cold Tris buffer (20 mM Tris, pH 7.5) containing 137 mM NaCl, 2 mM EDTA, 1% Triton X, 10% glycerol, 50 mM NaF, 1 mM DTT and a protease inhibitor cocktail (Roche Applied Science). A measure of 20 mg of cell lysate was then separated by 10% SDS-PAGE, transferred to Immobilon-P membranes (Millipore). After blocking with 5% nonfat milk and 0.1% Tween-20 in Tris-buffered saline, membranes were incubated with anti-STAT1 rabbit polyclonal antibody (Cell Signaling, Beverly, MA, USA). The blots were visualized using enhanced chemiluminescence (Amersham).
Flow cytometry analysis
After treating the cell lines with 100 U/ml IFN-g for 48 h, they were incubated first with fluorescein isothiocyanate (FITC)-conjugated anti-HLA-DR antibody (L243, ATCC), washed, and then incubated with affinity-purified, fluorescein-labeled goat anti-mouse IgG þ IgM secondary antibody (Kirkegaard & Perry Laboratories, Gaithersburg, MD, USA). Groups of about 30 000 stained cells were then subjected to FACScan flow cytometry (Becton Dickinson Biosciences, Braintree, MA, USA), and the data obtained were analysed using CellQuest software (Becton Dickinson Biosciences).
Plasmids and transfection
The expression vector pIRES-CIITAPIV, which was constructed from HACIITA-PIV as previously described (Takamura et al., 2004) , was kindly provided by Dr Jeremy M Boss of Emory University School of Medicine. The RKO colorectal cancer cell line was first cultured in Dulbecco's medium supplemented with 10% FBS. Cells (1 Â 10 6 ) were transfected with either pIRESouro (Clontech Laboratories, Palo Alto, CA, USA) or pIRES-CIITAPIV by electroporation using Nucleofactor according to the manufacturer's instructions (Amaxa, Germany). Briefly, 2 Â 10 6 cells were resuspended in 100 ml of Nucleofactor solution V (Amaxa) and then mixed with 3 mg of vector DNA. After transfection, the cells were plated and cultured in DMEM supplemented with 10% FBS and 0.5 mg/ml puromycin. After 2 weeks of selection, immunofluorescent staining for HLA-DR was carried out (see below).
Immunohistochemical staining
Cells were fixed in 3.7% formalin solution for 10 min at 251C, washed with PBS, and incubated with rabbit anti-human HLA-DR (MBL, Nagoya, Japan) overnight. Immunofluorescent staining for phosphorylated STAT1 was carried out using antiphospho-STAT1 antibody (Cell Signalling) and Alexa 488 anti-mouse IgG (Cosmo Bio, Tokyo Japan), which served as the secondary antibody. Finally, the nucleus was stained with Vectashield mounting medium with DAPI (Vector Laboratories, Inc, Burlingame, CA, USA), and the cells were examined under a fluorescence microscope (Olympus, Tokyo, Japan). For immunohistochemical analysis of primary tumors, sections were dewaxed with xylene, and then incubated in a 100-50% ethanol series. The tumors were then divided into three groups according to the observed percentage of HLA-DR-positive tumor epithelium: 0-5, 5-50 and >50%, respectively. Samples with 0-5% positive cells were considered negative, whereas samples with 5-50% positive cells were classified as weakly HLA-DR-positive, and those >50% as strongly HLA-DR-positive.
Chromatin immunoprecipitation analysis (ChIP)
ChIP was carried out as described previously (Magdinier and Wolffe, 2001) . Briefly, cells were harvested, and the proteins were cross-linked to DNA by adding formaldehyde to a final concentration of 1.0% for 10 min at 371C. After allowing the fixed cells to settle on ice for 10 min, they were spun down by brief centrifugation, and the supernatant was carefully aspirated. The cells were then washed with ice-cold PBS containing protease inhibitors and resuspended in lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.0, and protease inhibitor). Nucleoprotein complexes were sonicated to reduce the DNA to fragments ranging from 200 to 1000 bp in size, after which immunoprecipitation was carried out for 16 h at 41C with rotation, using anti-acetylated histone H3 antibody (Upstate Biotechnologies, Lake Placid, NY, USA) and anti-dimethylated histone H3K9 (Nakagawachi et al., 2003) as probes. The resultant immune complexes were collected using protein A-agarose beads, after which the DNA was purified by phenol/chloroform extraction, precipitated with ethanol and resuspended in water. About 1/100 of the precipitated DNA was used for PCR; 1/100 of the solution before adding antibody was used as an internal control for the amount of DNA. PCR was carried out in solution containing 1 Â PCR buffer (TaKaRa), 1 mM primers, 0.25 mM dNTP mixture and 1.0 U of Hot Start Taq polymerase (TaKaRa). The primer sequences for the PCR reaction are shown in Table 2 . The amplified products were subjected to agarose gel electrophoresis, and the intensity of resultant bands was calculated using a Lane and Spot Analyser (Atto, Japan).
